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further analyze EVPWe developed a modified protocol, based on differential ultracentrifugation (dUC), to isolate
extracellular vesicles and particles (specifically exomeres) (EVPs) from various human and murine
sources, including cell lines, surgically resected tumors and adjacent tissues, and bodily fluids,
such as blood, lymphatic fluid, and bile. The diversity of these samples necessitates robust and
highly reproducible protocols and refined isolation technology, such as asymmetric-flow field-
flow fractionation (AF4). Our isolation protocol allows for preparation of EVPs for various
downstream applications, including proteomic profiling.samples
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https://doi.org/10.1016/j.xpro.2020.100225SUMMARY
We developed a modified protocol, based on differential ultracentrifugation
(dUC), to isolate extracellular vesicles and particles (specifically exomeres)
(EVPs) from various human and murine sources, including cell lines, surgically re-
sected tumors and adjacent tissues, and bodily fluids, such as blood, lymphatic
fluid, and bile. The diversity of these samples requires robust and highly repro-
ducible protocols and refined isolation technology, such as asymmetric-flow
field-flow fractionation (AF4). Our isolation protocol allows for preparation of
EVPs for various downstream applications, including proteomic profiling.
For complete details on the use and execution of this protocol, please refer to
Hoshino et al. (2020).BEFORE YOU BEGIN
This protocol describes the isolation of small and heterogeneous EVPs from tissue culture superna-
tants (conditioned media) derived from cell lines or tissue explants as well as bodily fluids, such as
blood, lymphatic fluid, and bile. Below are listed the different sample types, their generation, and
pre-processing before EVP isolation.STAR Protocols 2, 100225, March 19, 2021 ª 2020 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1. Examples of typical cell culture conditions and EVP yields
Cell line
Type of culture dish,
growth area (cm2)
Cultured media
volume (mL) Cell number at seeding
Total EVP protein
yield
MDA-MB-231 T175 flask, 175 cm2 25–30 mL 2.0 3 106 cells 14.0 mg
MDA231-LM2-4175 T175 flask, 175 cm2 25–30 mL 1.8 3 106 cells 17.0 mg
4T1 150 mm plate, 148 cm2 25–30 mL 2.0 3 106 cells 50.0 mg
PANC-1 150 mm plate, 148 cm2 25–30 mL 8.3 3 106 cells 20.4 mg
AsPC-1 150 mm plate, 148 cm2 25–30 mL 9.0 3 106 cells 26.0 mg
Abbreviation: EVP, extracellular vesicle and particle
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OPEN ACCESS ProtocolCell culture conditions
Timing: 3–4 days
All cell lines are mycoplasma-tested prior to EVP isolation.
1. Prepare appropriate cell culture media, i.e., RPMI1640 or DMEM supplemented with penicillin
(100 U/mL), streptomycin (100 mg/mL) and 10% EVP-depleted fetal bovine serum (FBS).
a. We routinely prepare our own EVP-depleted fetal bovine serum (FBS). FBS is depleted of EVPs
by ultracentrifugation at 100,000 3 g for 70 min at 10C and sterile-filtered through a 0.2 mm
low protein-binding membrane. The EVP-depleted FBS can be stored in aliquots at 20C
(short term) and 80C (long term).
2. Culture cells at 37C, 5% CO2 in EVP-depleted media for 3–4 days until 80% confluence.
3. Collect conditioned culture media for EVP isolation. See Table 1 for typical cell culture conditions
and EVP yields.
CRITICAL: EVP-depleted FBS is also commercially available (Gibco #A2720801). Werecommend using the EVP-depleted FBS prepared using exactly the same method or
from the same commercial provider for any comparison study and to test each lot for
cell growth and EVP production in a cell culture system.2
CRITICAL: Avoid fully confluent cell cultures and maintain consistent culture conditions. Foreach cell line seeding number/density and culture time (48 to 72 h) need to be empirically
determined depending on growth rate. If using trypsin to harvest adherent cells, remember
to wash it off before seeding. Assess cell viability using a suitable method, i.e., manual cell
counting and trypan blue exclusion, automatic cell counting with dead cell discrimination or
flow cytometry with annexin V or propidium iodide, at the time of media collection.Tissue explant culture reagents and tools
Timing: 30 min
4. Prepare explant culture media: RPMI1640 supplemented with penicillin (100 U/mL) and strepto-
mycin (100 mg/mL).
a. Media needs to be warmed to ~15C–20C prior to use.
5. Sterilize surgical instruments (forceps, scalpel holder and scissors) by autoclaving (120C, 40 min,
dry cycle), otherwise use disposable instruments.
CRITICAL: For short-term (<16–18 h) tissue explant cultures use serum-freemedia to avoidintroducing bovine proteins and EVPs into the preparations. EVP-depleted media can also
be used depending on downstream applications and experimental aim, especially for long-
term cell cultures, such as explant outgrowth or organoid culture.STAR Protocols 2, 100225, March 19, 2021
ll
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Timing: approximately 20–30 min per mouse
6. Mouse organ harvesting.
a. Mice should be anesthetized with isoflurane (3.0% isoflurane at 2.0 L/min oxygen) delivered
through a nose cone and placed in a supine position before perfusing.
b. Perfuse mouse organs and flush blood out by injecting a bolus of 30 mL PBS/5 mM EDTA into
the left ventricle using a 26 G 3 1/2 needle and a 30 mL syringe.
c. Remove the organs of interest under aseptic conditions and immerse them in ice-cold sterile
PBS; place on ice until further dissection. Dissect organs in the biosafety cabinet.
Optional: Organ perfusion and harvesting can be performed after CO2 euthanasia, or other
IACUC approved methods, such as terminal anesthesia (pentobarbital), if an efficient work-
flow can be maintained.
CRITICAL: Aminimumof 5–10mice is required to isolate EVPs from normal organs. Tumor-bearing organs have higher EVP yields and 2–3 animals could be enough, depending on tu-
mor type and size. Matched organs should be pooled to obtain sufficient amounts of EVPs
for further characterization, such as nanoparticle tracking analysis (NTA), electron micro-
scopy (EM), and protein quantification (Bicinchoninic Acid Assay - BCA). Timely processing
of tissues within 30 min of harvest is required to ensure maximal EVP yield.Collection of blood and other bodily fluids
Timing: 10 min (blood samples), sample-dependent for other bodily fluids
Blood collection from patients and healthy subjects should typically be performed in themorning, or
after fasting. Phlebotomy training is required to perform the peripheral blood draw.
Bile collection can be performed by needle cannulation of the common bile duct at the time of sur-
gery. Bile is snap-frozen and stored at 80C until analysis.
Lymphatic fluid can be collected after radical lymphadenectomy from routinely used collection
drainage. To ensure that the sample of lymph fluid does not contain any surgical debris, only the
fluid released between 24 and 48 h should be collected (the fluid collected in the first 24 h is
discarded).
Downstream analysis of bodily fluid-derived EVPs follows the same isolation steps (Figure 1).
7. Collect the venous blood sample in EDTA (purple top) blood collection tube(s).
a. Invert the tube slowly, several times, immediately upon collection, to mix the blood with the
anticoagulant and prevent clot formation.
Note: One collection tube of 10 mL of whole blood typically yields approximately 5 mL of
plasma, which is usually sufficient for downstream applications, such as BCA, NTA, EM, pro-
teomic mass spectrometry (see further details in ‘‘Expected outcomes’’ section). We recom-
mend a minimum starting volume of no less than 1 mL of bodily fluid to ensure sufficient
EVP yield.
b. Place the tube of blood on ice to keep it cold during eventual transport.
CRITICAL: Occasionally invert the blood collection tube to avoid red blood cell lysis orclotting during transport.STAR Protocols 2, 100225, March 19, 2021 3




ProtocolNote: Blood collection from mice can be performed from the retro-orbital capillary sinus by
using a heparinized capillary tube. Alternatively, blood can be collected via cardiac puncture
in syringes containing anti-coagulants at the time of sacrifice. Approximately 50% of the blood
volume will be represented by plasma and murine blood should be processed in the same
manner as described for human samples. Cardiac puncture allows collection of 0.5–1.2 mL
of blood per animal. Retro-orbital collection allows for around 0.5 mL. We recommend to
use a minimum 1 mL of plasma which yields approximately 5 mg of EVPs. It is thus necessary
to combine the plasma of multiple mice to obtain enough plasma EVPs for analysis.Preparation of the AF4 instrument
Timing: 30 min
EVPs can be further separated into exomeres and distinct extracellular vesicle subpopulations by uti-
lizing asymmetric-flow field-flow fractionation (AF4) technology (Zhang et al., 2018). A detailed pro-
tocol encompassing the working principles, AF4 method development and troubleshooting, com-
parison with other technologies, limitations, and applications has been recently reported (Zhang
and Lyden, 2019). Here, we will focus our method description on preparation of the instruments prior
to fractionation and sample processing and recovery. In brief, we use the Eclipse AF4 (Wyatt Tech-
nology) system to fractionate samples in a short channel (144 mm length, Wyatt Technology). The
channel is equipped with a 10 kDa MWCO Regenerated Cellulose membrane (Millipore) on the
accumulation bottom wall and a 490 mm spacer. An Agilent Iso pump, autosampler, and fractionSTAR Protocols 2, 100225, March 19, 2021
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OPEN ACCESSProtocolcollector are included for running buffer, loading samples, and collecting fractions, respectively. On-
line real-time monitors include the Agilent Multiple Wavelength Detector (280 nm) and Wyatt Tech-
nology DAWN HELEOS II (multi-angle light scattering-MALS detector, at 664 nm) with QELS (dy-
namic light scattering-DLS detector) installed at detector 12 (100).
Optional: Assemble a new membrane for the short channel.
8. Equilibrate the system by running PBS at 1 mL/min for a minimum of 30 min.
9. Switch on lasers for all monitors ~15 min prior to sample loading.
10. Switch on thermostats for both the autosampler and fraction collector and set temperature at
4C, keeping samples and fractions at 4C throughout the whole fractionation process.
Optional: Coat the membrane with BSA by running 30–40 mg BSA 2–3 times using the
following method (this step is only needed when a new membrane is installed).











L-GlutaElution, 2 min, Vx (cross flow) 1.5 mL/min;
Focus, 1 min, Vx 1.5 mL/min;
Focus + Injection, 2 min, Vx 1.5 mL/min, injection flow 0.2 mL/min;
Elution, 15 min, Vx 3 mL/min;
Elution, 5 min, Vx 0 mL/min;
Elution + Injection, 5 min, Vx 0 mL/min;11. Pre-chill 96-well fraction collection plates by storing them in a cold room before use. Before
starting the fractionation process, install two plates in the designated positions (pre-set in the
Chemstation operating program).
CRITICAL: For long-term storage (>1-2 weeks), the system should be maintained in 20%ethanol. Flushing the system first with a large volume of water is essential before switching
to PBS buffer to avoid precipitation. The PBS buffer should be filtered through 0.1 or
0.2 mm filter units. An inline filter can be used as well. For short-term storage (<1-2 weeks),
the system can be stored in water (preferred) or PBS and run in a Night Rinse mode
(0.2 mL/min).Note: The short channel membrane can perform well without a notable difference in particle
separation resolution for multiple runs. A new membrane should be installed when obvious
shifting of the elution peaks and/or noisy baseline occurs.
KEY RESOURCES TABLENT or RESOURCE SOURCE IDENTIFIER
cal samples
cancer and adjacent normal tissues,
bile, and lymphatic fluid
Memorial Sloan Kettering Cancer
Center and Yonsei Cancer Center
n/a
als, peptides, and recombinant proteins
PBS VWR Cat#45000-446
Sigma Cat#A1900
m-grade FBS VWR Cat#97068-085
etal bovine serum, exosome-depleted Fisher Scientific Cat#A2720801
Corning Cat#10-040-CV
Corning Cat#10-013-CV
mine, 1003 Corning Cat#25-005-CI
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Penicillin–streptomycin solution, 503 Corning Cat#30-001-CI
TrypLE Thermo Fisher Scientific Cat#12604-039P
UltraPure 0.5 M EDTA, pH 8.0 Corning Cat#15575020
Isoflurane solution (formerly IsoThesia) Covetrus Cat#11695067772
Deuterium oxide Sigma Cat# 1133660500
Critical commercial assays
Pierce BCA Protein Assay Kit Thermo Fisher Scientific Cat#23225
Experimental models: cell lines
Human: MDA-MB-231 ATCC HTB-26
Human: MDA-MB-4175 Dr. J. Massague (Minn et al., 2005) n/a
Human: PANC-1 ATCC CRL-1469
Human: AsPC-1 ATCC CRL-1682
Mouse: B16-F10 ATCC CRL-6475
Mouse: 4T1 ATCC CRL-2539
Experimental models: organisms/strains
Mouse: wild-type BALB/c Jackson Laboratory Cat#000651
Mouse: wild-type C57BL/6 Jackson Laboratory Cat#000664
Software and algorithms
Astra 6 with an Eclipse module integrated to
operate flow
Wyatt Technology n/a
ChemStation Agilent Technologies n/a
Other
Ultracentrifuge Beckman Coulter https://www.
beckmancoulter.com/
Optima XE/XPE, Cat#A94469
Fixed-angle rotor 50.4Ti Beckman Coulter Cat# 347299
Fixed-angle rotor 70Ti Beckman Coulter Cat# 337922
Fixed-angle rotor 45Ti Beckman Coulter Cat# 339160
Ultracentrifugation tube (45Ti rotor) Beckman Coulter Cat#355628
Ultracentrifugation tube (70Ti rotor) Beckman Coulter Cat#355631
Ultracentrifugation tube (50.4Ti rotor) Beckman Coulter Cat#355645
500 mL Supor MachV PES filter units VWR Cat#73520-984
Integra disposable scalpel blades no. 10 Miltex REF 4-410
Mouse Surgical Kit Kent Scientific INMOUSEKIT
26 G 3 1/2 in PrecisionGlide needle Becton Dickinson Cat#305111
Cell strainer, 40 mm Corning Cat#CLS431750
Millex-GV Filter, 0.22 mm Millipore Cat# SLGVV255F
96-well plate VWR Cat#62406-081
Blue screw caps Agilent Cat#5182-0717
Screw cap vials Agilent Cat#5182-0714
Vial insert, 250 mL pulled point glass Agilent Cat#5183-2085
96-well plate, 1.0 mL, polypropylene Agilent Cat#8010-0534
Sealing tape, clear polyolefin Thermo Fisher Scientific Cat#232701
Amicon Ultra-15 Centrifugal Filter Unit with
Ultracel-30 membrane
Millipore Cat#UFC903024
Amicon Ultra-4 Centrifugal Filter Unit with
Ultracel-30 membrane
Millipore Cat#UFC803024
Millipore Reg. Cellulose membrane 10KD SC Wyatt technology Cat#4057
Inline filter membrane (0.1 mm) Wyatt Technology Cat#1871
1260 Infinity analytical- and preparative-scale
fraction collectors
Agilent Cat# G1364C
1290 thermostat Agilent Cat#G1330B
1260 Infinity standard autosampler Agilent Cat#G1329B
1260 Infinity multiple wavelength detector Agilent Cat#G1365D
1260 Infinity isocratic pump Agilent Cat#G1310B
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
TG-14 HPLC vacuum degasser GASTORR Cat# TG-14
DAWN HELEOS II with QELS installed at
detector 12 (100)
Wyatt Technology n/a
Eclipse AF4 Wyatt Technology n/a
Short channel Wyatt Technology n/a
Tabletop Heraeus Multifuge x3R centrifuge Thermo Fisher Scientific Cat#75004501
Microcentrifuge Eppendorf Cat#5424R
AccuScan GO UV/vis microplate
spectrophotometer
Fisher Scientific Cat#14-377-579
BD microtainer, capillary blood collection tube
hematology K2 EDTA additive
Becton Dickinson Cat#365974
Micro-hematocrit capillary tubes Kimble Chase Cat#41B2501
BD Vacutainer Red Top blood collection tube Becton Dickinson Cat#366434G
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Sucrose/deuterium oxide mixture for density purification
A sucrose/deuterium oxide mixture can be used to further purify EVP samples by a density cushion.Reagent Final concentration Amount
Sucrose 30% 15 g
Tris (Trizma base, Sigma) 20 mM 1.2 g
D2O n/a Fill to 48 mL
HCl n/a 1–2 mL
Total n/a 50 mLTo prepare the sucrose/deuterium oxide mixture (density 1.210 g/cm3), weigh sucrose and Tris and
add D2O. Shake until completely dissolved and measure the pH of the mixture. Adjust the pH to 7.4
with HCl and correct the volume to 50 mL. Filter the mixture through a 0.22 mm filter into a sterile
tube. The prepared sucrose mixture will be stable for one month at 4C. After this period, measure
the pH and adjust to 7.4.
CRITICAL: HCl is highly corrosive and irritant and can cause serious eye and skin damageand respiratory irritation. Handle HCl in a chemical hood and use protective clothing, gog-
gles, and gloves.Note: We recommend keeping ultracentrifuge rotors in 4C cold rooms and setting the tem-
perature of the ultracentrifuge to 10C to extend the life expectancy of the machine.
Alternatives: Alternatives to ultracentrifugation with sucrose/deuterium oxide cushion for
further clean-up and purification of EVP samples are ultrafiltration, size-exclusive chromatog-
raphy, two-phase isolation, magnetic capture, immunoprecipitation, density gradient (such as
Optiprep) and microfluidic devices. The outcome of these alternatives has to be determined
by the end user. As an alternative for fixed-angle rotors mentioned in this protocol, swing
buckets could also be used but specific handling, such as supernatant removal and pellet
re-suspension will have to be optimized by the user.STEP-BY-STEP METHOD DETAILS
Isolation of EVPs from cell culture
Timing: 3.5–4 h (time increases with number of samples)STAR Protocols 2, 100225, March 19, 2021 7
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OPEN ACCESS ProtocolPerform serial centrifugation and ultracentrifugation steps to isolate EVPs from conditioned cell
culture media.
1. Harvest culture media and remove cells, debris, apoptotic bodies, and contaminants through
serial centrifugation.
a. Centrifuge sample at 500 3 g for 10 min at 4C to pellet cells and debris.
b. Collect the supernatant without disturbing the cell/debris pellet. This can be done by quickly
pouring off the supernatant into a new container/tube or carefully pipetting off the superna-
tant. It is essential to work as quickly as possible during these steps, as the pellet will become
dislodged over time.
Note: For this and all subsequent steps, supernatants and re-suspended EVP pellets should
be kept on ice between isolation steps.
Note: A step of 3,000 3 g centrifugation for 20 min at 4C should be added for cell
culture supernatants before short-term storage (<24 h) at 4C or before freezing to remove
additional cell debris contaminants. This step has to be performed if further analysis of the
post-12,000 3 g microvesicle sample is planned.
Pause Point: Conditionedmedia supernatants can be stored at80C for long-term storage or
at 4 C for short-term (<24 h) storage before ultracentrifugation. Minor differences have been
observed between EVPs isolated from fresh versus frozen samples in terms of yield and purity.
However, frozen samples are often used to allow for retrospective studies, collaborative studies
between different institutions and batch processing of test samples/subjects and controls.
c. Centrifuge the supernatant at 12,000 3 g for 20 min at 4C to remove apoptotic bodies and
aggregates and larger vesicles that could otherwise be co-isolated with EVPs and ‘‘contami-
nate’’ the EVP preparation.
Note: This step can be performed in the ultracentrifuge or tabletop centrifuge depending on
volume and availability of the ultracentrifuge. We recommend performing the 12,0003 g spin
right before ultracentrifugation since contaminating material could develop by freeze-thaw
cycles or extended storage times.
d. Collect supernatant without disturbing the pellet and transfer to new/clean ultracentrifuge
tube by pipetting, leaving a small volume behind to avoid contamination from pellet.
CRITICAL: Wash newly purchased ultracentrifugation tubes with soap and water and rinsethem extensively in ddH2O before the first EVP isolation, since the factory coating on the
inside of the tube will prevent the EVP pellet from adhering to the tube. After use, the
tubes should be washed extensively and sterilized by autoclaving if required. Cleaning
of ultracentrifugation tubes was performed as per standard cleaning procedure for labo-
ratory glassware and utensils used for molecular and cellular biology applications. We
extensively wash the tubes in soap and hot water while scrubbing with a brush. The tubes
are then thoroughly rinsed with tap water to remove any traces of soap, followed by addi-
tional rinses in ddH2O. If EVPs are isolated for in vitro or in vivowork rather than molecular
biology, the tubes can be autoclaved, this however shortens the life of the tubes. No
contamination between samples has ever been observed using these procedures. The
tube used depends on the volume of starting material rather than the type of specimen.8
Note: It is important to avoid disturbing the pellet with the pipette tip in these centrifugation
steps since the aim is to remove pelleted contamination; instead, leave a minimal amount of
media above the pellet to avoid dissociating the pellet. Remember to work as quickly as
possible during these steps as the pellet will become dislodged over time.STAR Protocols 2, 100225, March 19, 2021
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OPEN ACCESSProtocol2. Isolate EVPs by ultracentrifugation
a. Centrifuge supernatant at 100,000 3 g for 70 min at 10C in a fixed-angle rotor in a Beckman
Coulter ultracentrifuge (see Materials and equipment) to collect EVPs.




ultNote: Before inserting tubes into the rotor, we recommend marking an area on the bottom of
the tube where the pellet is expected to form, since it may not be easily visible. Avoid disturb-
ing the pelleted area when discarding the supernatant and pay careful attention to it for suc-
cessful retrieval of your EVP pellet (Figure 2).
b. Discard the supernatant by decanting or carefully pipetting without disturbing the pellet. If pi-
petting off the supernatant, keep the tip of the pipet on the side of the tube opposite from the
pellet. If decanting the supernatant, be sure to pour the supernatant off the side of the tube
opposite the pellet and use one quick, careful motion to invert the tube.
Optional: Store supernatant if interested in EVP-depleted media for measurement of other
secreted factors, such as cytokines.
Note: In this and subsequent steps it is important to work quickly and remove the supernatant
as fast as possible after the ultracentrifuge has stopped to prevent dissociation of the pellet.
After removing the supernatant, leave the pellet untouched and place the inverted tube in a
rack for 1–3 min to avoid backflow of liquid. This ensures minimal carryover of contaminants
and prevents dissociation of the pellet. Remove drops of liquid from tube walls by vacuum
aspiration or using a Kimwipe, if necessary. Troubleshooting 1.
c. To wash the pellet, re-suspend it in 500 mL of cold PBS by pipetting and flushing the
marked area at the bottom of the ultracentrifugation tube. Ensure the pellet is re-suspended
well so contaminants trapped in the pellet (free, abundant proteins) are washed away.
Transfer the re-suspended pellet to a new ultracentrifuge tube and add 3 mL (tube
#355645), 20 mL (tube #355631) or 44 mL (tube #355628) of cold PBS. We recommend using
the same size tube throughout the protocol (i.e., depending on starting volume) since the
starting volume affects the yield. Thus, small volumes, 1–3 mL should be spun in a small
tube where these fewer EVPs can more readily be collected and concentrated. Trouble-
shooting 2.
d. Centrifuge the re-suspended pellet at 100,000 3 g for 70 min at 10C to collect the washed
EVP pellet.ure 2. Careful handling of the EVP pellet
After ultracentrifugation, carefully decant supernatant and (B and C) re-suspend the pellet in a small volume of PBS
–1 mL depending on tube size) by pipetting and flushing the marked area of the lower side of the
racentrifugation tube. Avoid generating bubbles.




Protocole. Discard the PBS supernatant by decanting and remove all liquid by gently tapping the in-
verted tube to avoid backflow.
f. Re-suspend the EVP pellet in 100 mL (see note for range below) of cold PBS and store at80C.
Reserve 10 mL aliquots for downstream quantification and characterization, such as protein
quantification, NTA, and EM, to avoid freeze-thaw cycles.
Note: The final re-suspension volume can be adjusted to create an appropriate concentration.
As low as 50 mL or up to 500 mL can be used for high yields depending on the total EVP yield.
Because cell lines vary in their EVP production, we recommend that users empirically establish
their own EVP yield for each cell type. Final concentrations will depend on downstream appli-
cations but should be above the lower limit of detection of the BCA assay or other assay for
protein quantification. If desired, the EVP pellet can be re-suspended directly in cell lysis
buffer for downstream RNA or protein applications.
Optional: After thawing of stored EVP samples and before downstream applications, depend-
ing on the type of downstream analysis, an additional centrifugation at 12,0003 g for 5 min at
4C can be performed to remove potential aggregates/precipitates formed during storage.Isolation of EVPs from tissue samples
Timing: 2 days
This section describes culture of dissected tissue explants and serial centrifugation steps to isolate
EVPs from conditionedmedia. Fresh human tumor tissues and peritumoral adjacent tissues were ob-
tained from patients surgically treated at Memorial Sloan Kettering Cancer Center (MSKCC) and
Yonsei Cancer Center (YCC). The ages of patients ranged from 3 to 88 years old. All individuals or
legal guardians provided informed consent for tissue donation according to protocols approved
by the institutional review board of MSKCC, WCM, and YCC (IRB 11-033A, 16-774, 16-1514, and
15-015, MSKCC; IRB 0604008488, WCM; IRB 4-2019-0811, YCC). The study is compliant with all
relevant ethical regulations regarding research involving human participants. All mouse experi-
ments were performed in accordance with Institutional Animal Care and Use Committees (IACUC)
and American Association for Laboratory Animal Science (AAALAS) guidelines (Weill Cornell Med-
icine animal protocol 0709-666A). Six to eight weeks old wild-type C57BL/6 or BALB/c female mice
were purchased from Jackson Laboratories.
1. Collect the tumor tissue and adjacent tissue in ice-cold PBS at the time of surgery and transfer
them on ice to the class II biosafety cabinet within 30 min.
Optional: Tissue weight can be used to normalize the EVP yield. Work quickly or in PBS to
avoid drying out tissue and decreasing EVP yield.
Note: Viability will vary between tissue explant cultures depending on a number of factors,
such as surgical approach, time to culture, and tissue composition. Viability can be assessed
using suitable methods such as manual cell counting and trypan blue exclusion, automatic cell
counting with dead cell discrimination dyes or flow cytometry with annexin V or propidium io-
dide. The process of making single cell suspensions can also affect the viability. We have
compared our dissected tissue explants to whole tissue explants and found similar, slightly
enhanced, viability in the dissected cultures (Figure 3).
2. Wash tissues in cold PBS 3 3 and quickly cut the tissues into 2 mm3-sized pieces. Rinse tissue
pieces again in PBS before plating if needed to remove debris and/or blood.STAR Protocols 2, 100225, March 19, 2021
Figure 3. Comparison of cell viability between whole tissue versus tissue dissected into smaller pieces
(A) Nanosight (NTA) profiles and protein concentration by bicinchoninic acid (BCA) assay for human colon that was cultured as whole tissue or dissected
into smaller pieces.
(B) Immunoblotting of lysates (20 mg of proteins) from baseline tissue (directly after collection, timepoint 0 h) immediately placed into lysing buffer
without culturing, whole tissue, and dissected tissue (after 12 h culture) derived from the human colon. PARP antibody (#9542, Cell Signaling
Technology [CST]), cleaved caspase-3 antibody (#9661S, CST), GAPDH antibody (#2118S, CST) were used for immunoblotting.
(C) Comparison of human colon whole tissue and dissected tissue cell viability as determined by dual Acridine Orange / Propidium Iodide fluorescence
and brightfield optics, using the LUNA automated cell counter. Live cells are green and dead cells are red.
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Protocol
Figure 3. Continued
(D) Comparison of human colon whole tissue and dissected tissue cell viability by apoptotic flow staining shows similar viability between baseline tissue
directly after collection and whole and dissected tissues after 12 h tissue explant culture.
(E) Comparison of cell viability between baseline and 24 h cultures of mouse lung tissue explant.
(F) Cell viability, as determined by flow cytometry with LIVE/DEAD Fixable Blue Dead Cell Stain, shows increased viability in dissected tissue cultures
compared to whole tissue culture from mice.
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interest, such as removal of adipose tissue, tumor and dissection of specific structures (i.e. tu-
mor margin), and thus, trained personnel is required.
3. Place tissue pieces in a 6-well plate (<10 pieces) or a 10-cm dish (10–15 pieces).
CRITICAL: It is important to limit the number of dissected tissues per dish to no more than15 pieces, which will minimize loss of tissue viability.4. If possible, allow tissue pieces to adhere to the plastic dishes for a fewminutes before addingme-
dia. Pipet media slowly against the side of the dish to avoid disturbing the tissue pieces. Ensure
enough media is added to cover the tissue pieces and try to minimize detachment from the plate.
Note: After initial media collection, consider adding EVP-depleted FBS and other essential
growth factors to culture media if establishing long-term viable cultures is desired. Alterna-
tively, organoids can be generated from the fresh tissue and EVPs can be continuously
collected from these organoid cultures.
5. Carefully transfer plates to 37C incubator with 5% CO2.
Note: Keep in a separate incubator reserved for ex vivo work, away from routine mycoplasma-
free cell cultures, if feasible.
6. After 16–18 h, carefully collect culture media without disturbing tissue explants, especially if
continuous culturing is planned. Keep the collected media on ice.
7. Centrifuge explant culture media according to the centrifugation steps described above for EVP
isolation from cell cultures.
a. Centrifuge the culture media at 5003 g for 10 min at 4C. Remove supernatant to a new tube.
b. Centrifuge the supernatant at 3,0003 g for 20 min at 4C. Remove supernatant to a new tube.
c. Centrifuge the supernatant at 12,0003 g for 20min at 4C, in either a tabletop centrifuge or in
the ultracentrifuge, depending on volume.
CRITICAL: Given the complex nature of tissue samples and the presence of significantdebris compared to cell lines, always perform all three pre-ultracentrifugation steps
(5003 g, 3,0003 g, and 12,0003 g) mentioned above to remove insoluble material. Addi-
tional filtrations and purification steps can be added as described below.8. Isolate EVPs by ultracentrifugation at 100,000 3 g for 70 min at 10C.
Optional: If further purification of a tissue sample EVP pellet is desired, re-suspend the EVP
pellet in 2.5mL of PBS and slowly overlay onto a 0.5mL sucrose/deuterium oxide cushion layer
by tilting the tube to 45; then centrifuge at 100,0003 g for 70min at 10C (Figure 4). Aspirate
the lower fraction using an 18 G needle and 3 mL syringe. Ensure not to disturb the layers or
eventual pellet and collect a volume similar to the amount of sucrose/deuterium oxidemixture
added (0.5 mL here). Note: the amount of sucrose/deuterium oxide mixture will depend on
the volume of the sample/ultracentrifugation tube size used and should be used in a ratio
of 1:5 sucrose/D2O:EVP/PBS suspension (Lamparski et. al, 2002). The end user will need to12 STAR Protocols 2, 100225, March 19, 2021
Figure 4. Ultracentrifugation of tissue sample EVPs over a sucrose/deuterium oxide density layer
(A) EVPs re-suspended in PBS could be further purified by overlaying onto a sucrose/deuterium oxide cushion and
centrifuging at 100,000 3 g, resulting in a lower EVP-enriched layer that could be aspirated from the upper layer
containing any potential contaminants.
(B) Aspiration of the lower fraction using an 18G needle and 3 mL syringe.
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bleshooting 3.
9. Re-suspend EVP pellet in 3 mL of PBS to wash and collect by ultracentrifugation at 100,000 3 g
for 70 min at 10C.
10. Discard the supernatant and re-suspend collected EVP pellet in 100 mL of PBS.
11. Store at 80C. Save 10 mL aliquots for protein quantification, NTA, and EM to avoid freeze-
thaw cycles.Isolation of EVPs from blood samples and other bodily fluids
Timing: 4 h
This section describes differential centrifugation steps to isolate EVPs from whole blood or bodily
fluids, such as lymphatic fluid, and bile. Human blood and bodily fluids were obtained from patients
treated at Memorial Sloan Kettering Cancer Center (MSKCC). The ages of patients ranged from 1 to
83 years old. All individuals or legal guardians provided informed consent for blood/fluid donation
according to protocols approved by the institutional review board of MSKCC (IRB 11-033A, 16-774,
16-1514, and 15-015; MSKCC, IRB 0604008488, WCM). The study is compliant with all relevant
ethical regulations regarding research involving human participants. All mouse experiments were
performed in accordance with Institutional Animal Care and Use Committees (IACUC) and American
Association for Laboratory Animal Science (AAALAS) guidelines (Weill Cornell Medicine animal pro-
tocol 0709-666A). Six to eight weeks old wild-type C57BL/6 or BALB/c female mice were purchased
from Jackson Laboratories.
1. Remove cells, debris, apoptotic bodies, and other contaminants by serial centrifugation steps.
a. Centrifuge the EDTA tube containing the blood at 500 3 g for 10 min at 4C. The blood will
separate into a lower layer containing red blood cells (RBC) and white blood cells (WBC) and
an upper layer of plasma
Note: The plasma should be yellow and clear but not red, which is a sign of RBC lysis at collec-
tion that could potentially affect and contaminate the EVP preparation. Following blood
collection in anti-coagulant-coated tubes, we follow the manufacturer’s protocol, and roll/
invert tubes several times, to ensure the blood is mixed with the anti-coagulant, thus mini-
mizing clotting and hemolysis. However, if visual observation of hemolysis is not sufficient
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absence of hemolysis by the lack of a spectrophotometric absorbance peak for free hemoglo-
bin at 414 nm (Tulkens et al., 2020). Additionally, the presence of large amounts of lipids, as
indicated by a cloudy appearance, might indicate the failure of fasting in subjects prior to
blood collection. Consider excluding such samples.
Note: For bile samples, and other very viscous samples, such as pancreatic duct fluid, add ice-
cold PBS at a ratio of 1:1 and homogenize the mixture by repeated pipetting. Follow the same
isolation steps as for blood.
CRITICAL: It is important not to disturb the pellet after each centrifugation step. Instead,collect most of the plasma while leaving a small residual volume above the pellet. We
recommend handling a maximum of 10 plasma samples at one time since additional sam-
ples will increase the delay and the risk of EVP loss.b. Collect the plasma by pipetting the top layer without touching the interphase layer and trans-
fer into a new tube.
c. Centrifuge the plasma at 3,0003 g for 20 min at 4C. This step will remove platelets that could
otherwise be co-isolated with EVPs and contaminate the EVP preparation.
Note: Platelet numbers can be assessed by classic hemocytometer counting, cell counting
with size exclusion or more precisely through flow cytometry of the platelet suspension
stained for CD61 (platelet glycoprotein IIb, broadly expressed on resting and activated
platelets).
d. Collect the plasma and discard the platelet-rich pellet if not needed.
Pause Point: The plasma can be frozen at 80C for long-term storage.
e. Centrifuge the plasma at 12,0003 g for 20min at 4C in either a tabletopmicrocentrifuge or in
an ultracentrifuge.
Note: This step will remove apoptotic bodies and larger vesicles that could otherwise be co-
isolated with EVPs and contaminate the EVP preparation.
Optional: The sample can be further processed to remove contaminants, such as lipids, by
filtering the cleared post-12,000 3 g plasma supernatant through a 1.2 mm membrane.
Note: We recommend performing the 12,000 3 g spin right before the ultracentrifugation
steps, especially for plasma and other bodily fluids as well as tissue-derived media, since pro-
tein aggregates and precipitates could develop through freeze-thaw cycles or over extended
waiting times.
Optional: After the 12,000 3 g spin, save 100 mL aliquots of cleared plasma for EVP quantifi-
cation and characterization by NTA.
2. Isolate EVPs by ultracentrifugation.
a. Transfer the plasma supernatant to an ultracentrifuge tube (see Materials and equipment). For
plasma, we recommend the 50.4Ti rotor with the #355645 tube for volumes up to 4 mL.
b. Centrifuge sample at 100,000 3 g for 70 min at 10C in a fixed angle rotor in a Beckman
Coulter ultracentrifuge (see Materials and equipment).
c. Decant or carefully pipet off the plasma, leaving the pellet untouched; place the inverted tube
in a tube rack to drain and to avoid liquid backflow. Note the volume of plasma for calculating
EVP numbers and protein per milliliter plasma.
3. Re-suspend the EVP pellet in 500 mL of ice-cold PBS and transfer to a second ultracentifuge tube.
4. Add 3.5 mL of PBS to wash the pellet.STAR Protocols 2, 100225, March 19, 2021
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6. Discard the supernatant by decanting and ensure there is no liquid backflow onto the pellet.
7. Re-suspend the pellet in 100 mL of PBS. Store at 80C. Save aliquots for protein quantification,
NTA, and EM to avoid freeze-thaw cycles.
CRITICAL: EVPs can also be isolated from serum (in a red top blood collection tubewithoutanticoagulant, Cat#366434G) using the same procedure; however, serum EVPs and plasma
EVPs are not equivalent.Note: The complex nature of plasma and heterogeneity between patients makes EVP isola-
tion challenging. Additional filtering and PBS dilutions can be made but could also introduce
loss or bias. Optimization protocols are being developed to decrease the inter-sample varia-
tion in EVP isolation from blood. See further discussion under ‘‘Limitations’’ section.
EVP sample preparation for AF4
Timing: 10 min
EVPs isolated from different sources via ultracentrifugation are pre-processed for AF4 analysis.
1. Adjust the protein concentration of freshly isolated or thawed frozen EVPs to 0.5–1 mg/mL with
PBS.
2. Pre-clear the EVP suspension by centrifuging in a tabletop microcentrifuge at 12,000 3 g at 4C
for 5 min to remove large protein and nanoparticle aggregates.
3. Transfer the supernatant into a pre-chilled screw cap vial. A pulled point glass vial insert can be
used for samples with small volume.
4. Place the sample vial into the designated position in the pre-chilled autosampler.
CRITICAL: To achieve the best resolution and yield, we have determined empirically that40–100 mg of EVP protein is required for EVPs isolated from conditioned media of cell cul-
ture for AF4 processing (with our instrument settings). Due to the size of the sample injec-
tion loop, which determines the maximum sample volume to be loaded, a sample concen-
tration range of 0.4–1 mg/mL is required for AF4. However, for EVPs derived from other
sources, these parameters need to be optimized empirically due to different EVP
complexity.AF4 of EVPs and data collection
Timing: 70 min
EVPs are separated based on their hydrodynamic sizes via AF4, and real-time data collection is car-
ried out for concentration and size determination.
1. Astra 6 (Wyatt Technology) is used for data acquisition and analysis, includingMALS, DLS, and UV
signals. Open a new experiment with the current configuration of the instrument, and set param-
eters for data collection: MALS data collection interval is 1 s and QELS interval is 2 s; total data
collection time is 60 min. Save the file and click ‘‘RUN.’’ Data collection automatically starts
once triggered by the autosampler sample loading.
2. Chemstation software (Agilent Technologies) with an integrated Eclipse module (Wyatt Technol-
ogy) is used to operate the AF4. First, program a new method or load the desired method from
the method library. The running method we have developed and optimized for EVP separation is




ProtocolElution, 2 min, Vx 0.5 mL/min;
Focus, 1 min, Vx 0.5 mL/min;
Focus + Injection, 2 min, Vx 0.5 mL/min, injection flow 0.2 mL/min;
Elution, 45 min, Vx a linear gradient decreasing from 0.5 to 0 mL/min;
Elution, 5 min, Vx 0 mL/min;
Elution + Injection, 5 min, Vx 0 mL/min;3. In Chemstation, set the input sample volume in the autosampler module (<=100 mL), and set the
parameters for fraction collection in the fraction collector module. Here, we collect fractions by
time slice (0.5 min/fraction).
4. Click ‘‘Run a single sample.’’ The sample will be automatically loaded and fractionated accord-
ingly, and data collection by Astra 6 will start once the sample loading is done.
5. Fractions are collected into 96-well plates based on time slice by the Agilent Fraction Collector.
6. After all samples have been processed for the day, switch off all lasers and thermostats for both
autosamplers and fraction collector. Switch on the COMET of the Dawn Heleos II detector for
~30 min to clean the flow cell. Change the buffer to water and run the Night Rinse mode ~16–
18 h. For long-term storage, the system can be stored in 20% ethanol after running a large volume
of water through the system.
CRITICAL: A blank control of the running buffer (i.e., PBS) can be run using the samerunning method in parallel to the EVP samples. This control can assist in evaluating instru-
ment performance, such as the background noise level and baseline drifting.Note: Samples more than 100 mg or of a volume larger than 100 mL can be sequentially frac-
tionated via AF4 using the same running method and fractions can be pooled together ac-
cording to their hydrodynamic sizes.
Pause Point: Collected fraction plates can be sealed with adhesive tapes and kept on ice in
4C for 2–3 days. However, we recommend proceeding to the next step of fraction concentra-
tion and characterization shortly after fraction collection if time allows.
Fraction concentration and characterization
Timing: 30 min or longer (timeframe varies based on the total amount of input samples to
be analyzed)
The size of EVP fractions is analyzed using the Astra 6 software and fractions of similar size are pooled
together for further concentration and downstream characterization.
1. In Astra 6, adjust the baseline of data collected from each monitor in the experiment just
completed and save the changes.
2. Open a new window of EASI Graph in Astra 6, and plot the hydrodynamic radius (Rh) of particles
vs Time. Please refer to Zhang and Lyden (2019) for the underlying principle of hydrodynamic
radius determination and fractionation efficiency evaluation using the Autocorrelation function.
Both QELS and UV absorbance are displayed on a relative scale to illustrate the relative abun-
dance of each subpopulation in the sample. A single peak or multiple peak regions can be
selected for analysis simultaneously.
Optional: Representative individual fractions can be first concentrated as described in steps
34–36 and a small aliquot can be subjected to negative staining TEM analysis for quick
morphology examination.
3. Guided by the particle size, abundance, and morphology, adjacent fractions with similar proper-
ties are then pooled together into 50 mL Falcon tubes and placed on ice.TAR Protocols 2, 100225, March 19, 2021
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OPEN ACCESSProtocol4. Pre-wet the Millipore centrifugal filter columns with Ultracel-30 membrane (30 kDa cutoff) with
cold PBS (fill to full) and spin in tabletop clinical centrifuge at 3,700 3 g at 4C for 5 min. Discard
the residual liquid in the filter unit and flow-through in the collection tube and place the filter col-
umn back into the collection tube.
5. Transfer the pooled fractions into the filter column (top part) and spin at 3,700 3 g at 4C for
7–8 min. Discard the flow-through but keep the samples retained in upper chamber of the filter
column (the concentrated sample).
6. Repeat step 34 until each pooled set is concentrated to the desired volume using a single filter
column.
7. Mix the concentrated samples gently and transfer to Eppendorf tubes on ice. For better recovery,
an additional volume of PBS can be added to rinse the filter column and combined with the sam-
ple.
8. Record the volume of the final product and remove an aliquot for BCA assay and/or NTA analysis
to determine the protein concentration and/or particle concentration. A small aliquot (~1 mg) can
be saved to verify particle integrity and morphology by TEM.
9. Use the EVP subsets immediately for downstream analysis or keep on ice for short-term storage.
Aliquots can be kept frozen at 80C for long-term storage.
CRITICAL: For EVP samples from a specific type of source material that has never beenanalyzed previously by AF4, it is critical to examine the morphology of EVPs present in
representative individual fractions by TEM first, before pooling fractions together for
further processing and analysis. NTA analysis is not applicable for exomeres, which, due
to their size, are below the detection limit of NTA technology (minimum size detected is
50 nm).Note: An alternative approach to concentrate a large volume of pooled fractions is ultracen-
trifugation at 100,000 3 g at 10C for 70 min. The pelleted EVP subsets can then be re-sus-
pended in the desired volume of PBS or other types of solution as required by downstream
analysis.
Note: This AF4 fractionation protocol is developed and optimized for EVPs isolated via
dUC method from conditioned media of cell culture. For complex samples, such as
plasma-derived EVPs, further preparation of samples prior to AF4 fractionation may be
required.EXPECTED OUTCOMES
Due to the recent interest in understanding the role of EVPs in inter-organ communication and their
value as biomarkers, the development of methods that could improve and optimize EVP isolation
protocols from different sources, such as blood and tissues, is critical.
Cell lines, as well as their EVPs, remain most valuable tools for functional studies, including cancer
research. However, we have shown that cell line EVPs do not always recapture the complexity and
heterogeneity of tissue samples, such as tumor explants (Hoshino et al., 2020). While a cell line
will produce EVPs specific for that tumor cell type, tumor explants contain a mixture of EVPs derived
from the tumor cells, tumor stroma, and infiltrating immune cells. Similarly, bodily fluids also contain
EVPs derived from distant organs, such as the liver and bone marrow. The lower complexity of cell
line-derived EVPs, compared to tissue explants or bodily fluids, makes them suitable for targeted
approaches, such as immunoaffinity-based isolation methods. Cultured cell lines lack the tissue or-
ganization and microenvironment, which may alter cell physiology and lead to differences in EVP
content and secretion, but they allow the study of EVPs derived from a single cell type source. To
overcome these shortcomings, patient-derived organoids can be used for EVP isolation, allowing
us to partially recapitulate the tissue architecture while limiting the sources of EVPs to one or twoSTAR Protocols 2, 100225, March 19, 2021 17
Figure 5. Dissecting tissues into 2 mm3 pieces improves EVP yields without affecting EVP morphology
(A) Nanosight (NTA) profiles for whole organs and tissue dissected into smaller pieces for murine normal lung and
metastasis-bearing lung.
(B) Transmission electron microscopy images of the same samples as in b, normal lung (upper row) and metastasis-
bearing lung (lower row).
(C and D) (C) Particle size for EVPs from normal lung and metastasis-bearing lung and (D) EVP protein yields from
whole tissue versus tissue dissected into smaller pieces. n = 3, mean and SD is shown; *p < 0.05.
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OPEN ACCESS Protocolcell types. Another advantage of using cell lines is the possibility to scale up cultures to obtain large
amounts of EVPs for downstream applications. For example, with our protocol, the commonly used,
commercially available human breast cancer cell line MDA-MB-231 (2 3 106 cells, 4 days of culture)
yields around 15 mg of EVP protein per 25 mL of media, and the well-known murine melanoma cell
line B16-F10 yields 35 mg of EVP protein per 15 mL of media after three days of a culture, initially
seeded with 1.53 106 cells. The amounts of EVPs will vary largely between cell lines and culture con-
ditions and therefore the scale of the culture will have to be empirically determined for each exper-
iment depending on the amount of EVPs required for downstream applications.
For optimization of EVP isolation from tissue samples, we used organs harvested from healthy wild-
type mice, murine metastatic lung tumor tissue, and human adjacent colon tissue (Figure 5). We
compared EVP yields from whole tissue/organs to dissected (2 mm3) pieces and performed the
following downstream characterization: total EVP protein amounts were measured by BCA; particle
number, size and concentration were measured by NTA; and morphology was determined by TEM.
Combining 5 BALB/c mice per group, we found that dissecting tissue explants into smaller pieces
resulted in an increase in EVP protein yields measured by BCA assay in all tested tissues (Table 2).
Similar results were observed when EVP number per mg of tissue was measured by NTA, showing
an increase in the number of EVPs in tissue explants that had been dissected into pieces. The
more pronounced increase in EVPs detected by BCA, compared to NTA suggests that the increase18 STAR Protocols 2, 100225, March 19, 2021
Table 2. Increased EVP yields from dissected tissue explant cultures versus whole tissue cultures
Tissue
EVP concentration by
BCA (ng/mL) EVP size by NTA (nm) The number of EVP particles by NTA (particles/mL)
Whole Dissected Whole Dissected Whole Dissected
Human
Colon 353.3 741.8 109 (G3) 107 (G2) 1.3 3 108 (G1.0 3 107) 3.1 3 108 (G2.0 3 107)
Mouse
Brain 29.1 329.4 134 (G6) 144 (G4) 3.2 3 108 (G2.9 3 107) 4.93108 (G1.8 3 107)
Kidney 12.0 42.2 140 (G4) 159 (G16) 6.8 3 108 (G7.63107) 2.6 3 108 (G1.93107)
Liver 83.1 247.2 116 (G5) 143 (G14) 2.3 3 108 (G1.0 3 107) 3.5 3 108 (G2.9 3 107)
Lung 11.1 209.8 120 (G1) 115 (G1) 4.7 3 109 (G5.4 3 107) 5.6 3 109 (G3.9 3 107)
Pancreas 44.6 188.5 178 (G27) 202 (G53) 7.2 3 107 (G8.1 3 106) 1.4 3 108 (G1.5 3 107)
Spleen 7.7 92.0 145 (G14) 163 (G27) 6.1 3 108 (G2.9 3 107) 5.33108 (G2.0 3 107)
Thymus 37.0 145.1 135 (G5) 138 (G11) 4.4 3 108 (G4.6 3 107) 2.6 3 108 (G1.2 3 108)
White adipose tissue 0.2 1,299.6 134 (G8) 130 (G10) 9.9 3 107 (G1.2 3 107) 6.4 3 108 (G6.2 3 107)
Brown adipose tissue 7.1 138.6 113 (G8) 153 (G16) 2.2 3 108 (G3.3 3 107) 2.0 3 108 (G2.3 3 107)
EVP size is similar between the two conditions. EVP protein concentration wasmeasured by BCA (ng/mL, left), EVP size (nm,middle) and concentration (number of
EVP/mg tissue) were measured by Nanosight (right) for human colon tissue and murine pancreas, white adipose tissue (WAT), brown adipose tissue (BAT), lung,
brain, spleen, thymus, kidney, and liver.
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to the increase in larger extracellular vesicles/exosomes (this has to be further confirmed by AF4 ex-
periments). Since downstream analysis protocols including proteomics and functional characteriza-
tion require at least 10 mg of EVP protein, andNTA and TEM require at least 1 mg, increasing the yield
of the tissue explant protocol ensures the feasibility of further experiments, while decreasing the
number of animals required (meeting the 3 Rs principle - replacement, reduction, refinement),
and reducing the cost of animal acquisition and maintenance. Taken together, these results demon-
strate that dissecting tissue explants into smaller pieces before culture for EVP isolation improves
EVP yield. However, it remains unclear whether dissected tissues versus whole tissue explants,
and the tissue explant culture process itself, can alter tissue biology, promoting changes in the
EVP cargo.
Bodily fluids are often rich in EVPs and 1 mL of fluid is sufficient to isolate enough material for down-
stream characterization and proteomics. Blood, as the most easily accessible fluid, can yield from a
few micrograms to 20 mg EVP protein per mL plasma whereas bile could be even richer and contain
up to double the amount of EVP protein (and ~13 108 EVPs/mL) compared to plasma. The amounts
will vary based on health status and other variables, such as cancer stage, treatment, etc.
AF4 separates EVPs based on their hydrodynamic size within a large dynamic range. As reported in
our recent work, AF4 facilitates the successful separation of distinct subsets of extracellular vesicles/
exosomes and the identification of exomeres (Zhang et al., 2018). A representative AF4 fractionation
profile of B16F10- derived EVPs and TEM images of pooled fractions corresponding to exomeres,
Exo-S, and Exo-L are shown in Figure 6.LIMITATIONS
Although the differential ultracentrifugation (dUC) protocol provides a robust methodology to pro-
cess and analyze a large number of specimens from different sources and with a wide range of sam-
ple volumes, it presents several limitations. dUC separates particles based on their hydrodynamic
size and density but the resolution and the resultant EVP purity is limited. Only several groups of
large vesicles, microparticles, and small EVPs (relatively enriched for exomeres and exosomes) are
isolated. Moreover, EVPs in each group will be heterogeneous and contamination by other non-
EVP proteins will likely occur (Théry et al., 2006; Tauro et al., 2012). Furthermore, the composition
of bodily fluids, such as blood plasma, is much more complex than most other types of specimens,STAR Protocols 2, 100225, March 19, 2021 19
Figure 6. Representative AF4 separation of EVPs prepared from B16F10 cells using differential ultracentrifugation
(A) Representative AF4 fractionation profile showing hydrodynamic radius (Rh) and fractograms of UV absorbance and
QELS plotted against time.
(B) Representative negative staining TEM images of combined fractions resolved by AF4 for corresponding exomeres,
Exo-S, and Exo-L subpopulations. Colored arrows: representative EVPs in each subpopulation (adapted from Zhang
et al., 2018).
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plasma of albumin, lipoproteins and other soluble proteins. These proteins/complexes cannot be
efficiently eliminated from the small EVP fraction by the dUC method. Moreover, some of the lipo-
proteins are within the size range of EVPs (e.g., LDL 18–28 nm in diameter; IDL, 25–50 nm; VLDL 30–
80 nm; Chylomicrons 75–600 nm). The presence of high amounts of contaminants can interfere with
specific downstream analysis, such as multi-omics profiling. Therefore, removal of these abundant
contaminants by coupling dUC with other separation strategies, such as immunoaffinity capture
or size-exclusion chromatography, based on distinct biophysical/biochemical properties of EVPs
is necessary to further improve the quality of EVP preparations and expand the dynamic range of
the analysis for EVP-based biomarker discovery. Accordingly, a larger volume of starting material
is usually required if additional purification procedures are included to yield enough EVP for final
analysis.
In the past decade, a variety of strategies have been developed for EVP isolation. Besides the dUC
method described here, examples include immunoaffinity capture (IAC), ultrafiltration (UF), size-exclu-
sion chromatography (SEC), polymer-based precipitation, and microfluidics (Théry et al., 2006; Chen
et al., 2010; Merchant et al., 2010; Lässer et al., 2012; Tauro et al., 2012; Jørgensen et al., 2013; Nakai
et al., 2016; Ko et al., 2017; Reátegui et al., 2018; Brennan et al., 2020). We recently reported the appli-
cation of AF4 for small EVP fractionation with improved resolution (Zhang et al., 2018; Zhang and Lyden,
2019). To choose themost suitablemethod for biomarker discovery using plasma samples, especially for
potential clinical translation, several critical factors have to be taken into consideration, including the
available specimen volume/size and the proposed downstream analysis. A compromise may have to20 STAR Protocols 2, 100225, March 19, 2021
Figure 7. Example of ‘‘contaminated’’ samples
purified over a sucrose/deuterium oxide density
layer
Aggregates and insoluble material could
contaminate the EVP pellet, especially in complex
samples, such as tissue explants or bodily fluids.
Purification methods, such as density cushion, could
be performed to improve sample purity.
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OPEN ACCESSProtocolbe made between purity and yield. Labor- and time-efficiency are important factors to consider, as well.
According to the MISEV2018 guidelines, dUC falls within the category of ‘‘intermediate recovery, inter-
mediate specificity’’ (Théry et al., 2018). Given that dUC is reproducible and commonly used, can be
quickly and easily mastered by researchers, and does not require specialized expertise or equipment,
it is still the most accessible methodology for EVP isolation. This is very important for studies requiring
cross-comparison and validation by multiple centers or studies involving sample collection and process-
ing over a relatively long timespan. Another reason for dUC remaining the gold standard for EVP isolation
is that no chemicals are used, thereby preserving the EV integrity, which is particularly important for
downstream functional studies.TROUBLESHOOTING
Problem 1
Variability in EVP yield.Potential solution
Despite using the same ultracentrifuge manufacturer, model, and rotors, we have observed variability in
EVP yield between different ultracentrifuges. Since each ultracentrifuge is unique, if possible, always use
the samemachine, or if it is necessary to use different or several machines, compare yields betweenma-
chines and ensure test samples and controls are prepared using the same machine.Problem 2
Low EVP yield.Potential solution
One option is to use a smaller sized tube to concentrate the collection of the EVPs in a smaller target
area at the bottom of the tube and avoid loss by washing in large amounts of PBS. Another possibility
is that the EVP pellet may be lost by dissolving into supernatant during prolonged handling times
between steps. Work quickly or handle fewer samples at a time to avoid this problem.STAR Protocols 2, 100225, March 19, 2021 21
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Especially when isolating EVPs from human samples, one can expect a variety of contaminants, such
as tissue debris and protein aggregates, and therefore extensive processing is necessary to remove
them and to achieve satisfactory quality of EVPs.
Potential solution
One approach for the purification of limited sample quantities is the use of a density separation step
(see description in protocol and Figure 7). Other options are filtration and additional pre-ultracen-
trifugation spins, or extensive washes, all of which will lead to some loss of material. For sucrose/
deuterium oxide cushion purification up to 50% loss in total EVP protein can be expected but de-
pending on downstream applications, specific EVP populations can also be enriched. Purification
steps should be included when the EVP product will be submitted for downstream ‘‘omics’’ analyses
for which higher purity of the product is required. We recommend using the sucrose cushion for tis-
sue explants where the collected EVP pellet still contains aggregates after the washing step, which
are typically observed for certain organs, such as pancreas and liver. This also depends partly on dis-
ease condition and needs to be determined by the investigator.
RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be ful-
filled by the Lead Contact, David Lyden (dcl2001@med.cornell.edu).
Materials availability
This study did not generate new unique reagents.
Data and code availability
The protocol includes all datasets generated or analyzed during this study. The study did not
generate new unique code.
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